FIREBRICK Pharma has signed a one-year Marketing Representation Agreement with Singapore-based Innorini Life Sciences to promote Nasodine Nasal Spray among healthcare professionals (HCPs) in Singapore.
Innorini will market Nasodine to general practitioners, hospital doctors, and pharmacists, aiming to drive awareness and facilitate on-site sales to patients.
"In Singapore, it is common practice for GPs and hospitals to dispense and sell products to patients," Firebrick Executive Chairman, Peter Molloy, explained.
"In this way, HCPs represent an important distribution channel for sales, as well as advocacy and recommendation."
Innorini's Managing Director, Rishi Nandiraju, expressed his excitement for the collaboration, saying, "we're thrilled to partner with Firebrick Pharma and to be able to introduce Nasodine, the world's first PVP-I nasal spray, to healthcare professionals in Singapore".
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Nov 24
